Document Detail


Adjuvant postoperative radiation therapy for rectal adenocarcinoma.
MedLine Citation:
PMID:  1524036     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
From October 1975 to August 1988, 261 patients at high risk for local recurrence after curative resection of rectal carcinoma underwent high-dose postoperative irradiation. Patients received 45 Gy by a 4-field box usually followed by a boost to 50.4 Gy or higher when small bowel could be excluded from the reduced field. Since January 1986, patients also received 5-fluorouracil (5-FU) for 3 consecutive days during the first and last week of radiotherapy. Five-year actuarial local control and disease-free survival decreased with increasing stage of disease; patients with Stage B2 and B3 disease had local control rates of 83% and 87% and disease-free survivals of 55% and 74%, respectively. In patients with Stage C1 through C3 tumors, local control rates ranged from 76% to 23%, and disease-free survivals ranged from 62% to 10%, respectively. For patients with Stage C disease, disease-free survival decreased progressively with increasing lymph node involvement, but local control was independent of the extent of lymph node involvement. For each stage of disease, local control and disease-free survival did not correlate with the dose of pelvic irradiation. Preliminary data from this study suggest a trend toward improved local control for patients with Stage B2, C1, and C2 tumors who receive 5-FU for 3 consecutive days during the first and last weeks of irradiation compared with patients who do not receive 5-FU. Current prospective randomized studies are addressing questions regarding the optimum administration of chemotherapy with pelvic irradiation for patients following resection of rectal carcinoma.
Authors:
C G Willett; J E Tepper; D S Kaufman; P C Shellito; R Eliseo; K Convery; W C Wood
Related Documents :
23748836 - Combined chemoradiation for head and neck region myxofibrosarcoma of the maxillary sinus.
20968136 - Importance of the circumferential extent of tumors and clinical lymph node status as pr...
1938526 - Combined radiation therapy, mitomycin c, and 5-fluorouracil for locally recurrent recta...
2418506 - Extrarectal colonic carcinoma: analysis of 138 cases with long-term follow-up.
24859366 - Activity of sl-401, a targeted therapy directed to the interleukin-3 receptor, in patie...
15737876 - Outcome following alemtuzumab (campath-1h)-containing reduced intensity allogeneic tran...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of clinical oncology     Volume:  15     ISSN:  0277-3732     ISO Abbreviation:  Am. J. Clin. Oncol.     Publication Date:  1992 Oct 
Date Detail:
Created Date:  1992-10-09     Completed Date:  1992-10-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8207754     Medline TA:  Am J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  371-5     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston 02114.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / drug therapy,  pathology,  radiotherapy*,  surgery*
Adult
Aged
Aged, 80 and over
Combined Modality Therapy
Female
Fluorouracil / therapeutic use
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Staging
Radiotherapy Dosage
Rectal Neoplasms / drug therapy,  pathology,  radiotherapy*,  surgery*
Survival Analysis
Chemical
Reg. No./Substance:
51-21-8/Fluorouracil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Avoiding cumulative trauma disorders in shops and offices.
Next Document:  Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy.